Search

Your search keyword '"Whitworth, Pat"' showing total 83 results

Search Constraints

Start Over You searched for: "Whitworth, Pat" Remove constraint "Whitworth, Pat" Search Limiters Full Text Remove constraint Search Limiters: Full Text
83 results on '"Whitworth, Pat"'

Search Results

1. Ask2Me VarHarmonizer: A Python-Based Tool to Harmonize Variants from Cancer Genetic Testing Reports and Map them to the ClinVar Database

2. Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King.

3. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

5. The integrals in Gradshteyn and Ryzhik. Part9: Combinations of logarithms, rational and trigonometric functions

8. Abstract P3-05-43: Germline Testing Results in Patients with Genomic Tumor Profiling

10. Abstract P6-02-09: Racial/Ethnic Groups Have Different Rates of Pathogenic Variants in Common Cancer Genes

11. Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database

12. Abstract P1-04-06: Characterization of recurrence risk after lumpectomy and radiotherapy in HER2-positive ductal carcinoma in situ of the breast, using 7-gene predictive biosignature: Implications for the NSABP-B43 trial results

14. Abstract PD14-05: PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women

15. Abstract P3-05-44: Genomic testing and Ki-67 Percentage: Two puzzle pieces being undervalued in breast cancer treatment

16. Abstract PD15-07: PD15-07 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy

17. P063: Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 individuals*

18. Abstract B016: Guiding de-escalation of treatment for patients with DCIS using a predictive 7-gene biosignature: Identification of a clinically low-risk patient group

19. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer

25. Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model

28. Abstract P3-18-01: Assessmentof DCISionRT for guiding radiotherapy of DCIS in Sweden

30. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)

33. Abstract PS4-04: Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

35. Abstract PS8-30: Longitudinal clinical outcomes of a multi-center universal genetic testing registry

36. Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy

38. Axillary Staging in the Setting of a Preoperative Diagnosis of Ductal Cancer In Situ (DCIS) : Results of an International Expert Panel and a Critical Guideline Performance Using Frequentist and Bayesian Analysis

39. Risk stratification in early stage luminal breast cancer patients treated with and without RT

40. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk

42. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk

43. Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

44. A Novel Automated Assay for the Rapid Identification of Metastatic Breast Carcinoma in Sentinel Lymph Nodes

45. FOXA1 and PR predict ipsilateral event risk and identify a group with strong radiation response in ductal carcinoma in situ (DCIS)

46. Validation of a multi-marker test that predicts recurrence in patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS)

48. Abstract P4-11-17: Validation of a multi-marker test that predicts recurrence in patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS)

49. Abstract P4-11-18: FOXA1 and PR predict ipsilateral event risk and identify a group with strong radiation response in ductal carcinoma in situ (DCIS)

50. Abstract P6-08-22: Functional subtyping with BluePrint 80-gene profile identifies two distinct triple positive subtypes with and without trastuzumab/chemo-sensitivity: Implications for treatment from the NBRST registry

Catalog

Books, media, physical & digital resources